SFL Pharma GmbH is a Pharmaceutical company based in Basel that provides full support to international pharmaceutical companies who do not have a registered entity in Switzerland.
SFL Pharma has a full Quality Management System and holds an Establishment License with Swissmedic and
- acts as a Market Authorization Applicant and Market Authorization Holder (MAH) in Switzerland,
- interacts with Swiss health authorities,
- manages the following activities:
- Regulatory Affairs
- Quality assurance
- Medical Affairs
- Supply Chain
- Public Affairs
At SFL Pharma, we are committed to operate in an ethical manner on the basis of Integrity, Fairness and Respect in all our activities. In 2017-2020, SFL Pharma GmbH did not provide any pecuniary benefits to healthcare professionals, healthcare organizations or patient organizations.
Shayesteh Fürst-Ladani is the CEO and founder of SFL Pharma.
Shayesteh leads the team at SFL Pharma and provides global strategic support for the development of healthcare products. Shayesteh is President of the not-for-profit associations “Rare Disease Action Forum” (RDAF) as well as the “Medtech & Pharma Platform” (MPP). She has extensive experience in negotiating companies’ interests at a senior level in meetings with stakeholders.
Before founding SFL Pharma, Shayesteh held senior positions as Head of Global Regulatory Affairs and Head of Regulatory Affairs for Development Products at various biotech and major pharmaceutical companies.
Shayesteh received her MSc in Microbiology from the University of Vienna, Austria and an MBA from the Open University Business School, Milton Keynes, UK. Shayesteh is IFAPP Global Fellow in Medicines Development (GFMD).
SFL Pharma is a member of the:
Rare Disease Action Forum (RDAF)
The Rare Disease Action Forum is a multi-stakeholder not-for-profit association that serves as a unique platform to exchange ideas and define actions to raise awareness of rare diseases and improve access to diagnosis, treatment and care for patients with rare diseases in Switzerland. The RDAF regularly organizes multi-stakeholder workshops including roundtables on rare disease related topics.
The Swiss Biotech Association is a non-profit organization representing the interests of the Swiss biotech industry. It aims to ensure a favourable regulatory framework as well as to facilitate access to talents, technologies and financial resources.
The European Association for Bioindustries (EuropaBio) is a European umbrella industry association for biotechnology. Its core mission is to represent the interests of the biotechnology industry at the European level. EuropaBio aims to promote an innovative and dynamic biotechnology-based industry in Europe, engage in an open, transparent and informed dialogue with all stakeholder about biotechnology and champion the socially responsible use of biotechnology.